Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $280.84 +0.99%
EPS Growth %: +409.4%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Vince Holding (VNCE) Tops Q1 EPS by 21c
- Laser Photonics Corporation (LASE) Reports Q1 Loss of $0.11
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
